Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Update

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 86,600 shares, a growth of 50.9% from the December 15th total of 57,400 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 50,200 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Daré Bioscience

An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC grew its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned approximately 9.25% of Daré Bioscience worth $262,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Trading Up 0.3 %

Shares of NASDAQ:DARE traded up $0.01 on Friday, reaching $3.34. 11,893 shares of the company traded hands, compared to its average volume of 22,963. The stock has a market capitalization of $29.06 million, a P/E ratio of -5.65 and a beta of 1.28. The business’s 50-day simple moving average is $3.30 and its 200 day simple moving average is $3.42. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.